Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTX-1001 in Relapsed and Refractory Multiple Myeloma
NCT05651932Phase 1Recruiting
- Sponsor
- K36 Therapeutics
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Countries
- 4
01
Overview
Phase 1, open-label trial of gintemetostat in multiple myeloma (MM) (4 cohorts), sponsored by K36 Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
gintemetostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05651932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651932.